Etalocib

Etalocib is a drug candidate that was under development for the treatment of various types of cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.

Etalocib

Names
Preferred IUPAC name 25-Ethyl-14-fluoro-22-hydroxy-82-propyl-3,7,9-trioxa-1,10(1),2(1,4),8(1,3)-tetrabenzenadecaphane-102-carboxylic acid
Other names LY293111 VML 295
Identifiers
CAS Number	161172-51-6 N
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL329123 Y
ChemSpider	154905 Y
IUPHAR/BPS	2948
KEGG	D04074 Y
PubChem CID	177941
UNII	THY6RIW44R Y
CompTox Dashboard (EPA)	DTXSID70167073
InChI InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37) Y Key: YFIZRWPXUYFCSN-UHFFFAOYSA-N Y
SMILES Fc1ccc(cc1)c4c(O)cc(OCCCOc3cccc(Oc2ccccc2C(=O)O)c3CCC)c(c4)CC
Properties
Chemical formula	C33H33FO6
Molar mass	544.619 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Clinical trials were conducted measuring efficacy for treatment of non-small cell lung cancer and pancreatic cancer and the inflammatory conditions asthma, psoriasis, and ulcerative colitis, but were suspended due to lack of efficacy.